Two Sigma Investments
RNAC icon

Two Sigma Investments’s Cartesian Therapeutics RNAC Stock Holding History

Two Sigma Investments’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.09M Buy
296,293
+128,980
+77% +$955K ﹤0.01% 2598
2026
Q1 		$1.03M Buy
167,313
+76,035
+83% +$542K ﹤0.01% 3248
2025
Q4 		$658K Buy
+91,278
New +$738K ﹤0.01% 3166
2025
Q2 		– Sell
-11,015
Closed -$145K – 3486
2025
Q1 		$145K Sell
11,015
-797
-7% -$14.2K ﹤0.01% 2907
2024
Q4 		$212K Sell
11,812
-1,099
-9% -$22.3K ﹤0.01% 2862
2024
Q3 		$208K Buy
+12,911
New +$202K ﹤0.01% 2793
2023
Q2 		– Sell
-6,711
Closed -$280K – 3225
2023
Q1 		$280K Sell
6,711
-3,873
-37% -$182K ﹤0.01% 2448
2022
Q4 		$359K Sell
10,584
-17,184
-62% -$731K ﹤0.01% 2171
2022
Q3 		$1.37M Buy
27,768
+23,504
+551% +$1.29M ﹤0.01% 1330
2022
Q2 		$168K Sell
4,264
-33,363
-89% -$989K ﹤0.01% 2196
2022
Q1 		$1.39M Sell
37,627
-10,916
-22% -$683K ﹤0.01% 1527
2021
Q4 		$4.75M Buy
48,543
+6,869
+16% +$739K 0.01% 1224
2021
Q3 		$5.2M Sell
41,674
-13,533
-25% -$1.63M 0.01% 1193
2021
Q2 		$6.92M Sell
55,207
-319
-0.6% -$38K 0.02% 1001
2021
Q1 		$7.54M Sell
55,526
-1,706
-3% -$212K 0.02% 838
2020
Q4 		$5.2M Buy
57,232
+31,080
+119% +$2.7M 0.01% 910
2020
Q3 		$1.95M Buy
26,152
+2,393
+10% +$183K 0.01% 1306
2020
Q2 		$2.02M Buy
23,759
+17,665
+290% +$1.6M 0.01% 1092
2020
Q1 		$441K Buy
6,094
+4,545
+293% +$439K ﹤0.01% 2030
2019
Q4 		$111K Buy
1,549
+1,162
+300% +$56K ﹤0.01% 3516
2019
Q3 		$20K Buy
+387
New +$20.6K ﹤0.01% 3384
2019
Q2 		– Sell
-6,171
Closed -$439K – 3614
2019
Q1 		$439K Sell
6,171
-512
-8% -$32.5K ﹤0.01% 2344
2018
Q4 		$533K Buy
6,683
+3,124
+88% +$713K ﹤0.01% 2060
2018
Q3 		$1.66M Buy
3,559
+669
+23% +$269K ﹤0.01% 1610
2018
Q2 		$1.15M Buy
2,890
+849
+42% +$301K ﹤0.01% 2048
2018
Q1 		$624K Buy
2,041
+45
+2% +$12.8K ﹤0.01% 2341
2017
Q4 		$587K Buy
1,996
+259
+15% +$113K ﹤0.01% 2322
2017
Q3 		$951K Buy
+1,737
New +$924K ﹤0.01% 1755

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Two Sigma Investments's RNAC Position: Q2 2026 in Review

Two Sigma Investments increased its Cartesian Therapeutics (RNAC) stake by 77% in Q2 2026, buying an estimated $955K and bringing the position to 296,293 shares worth $3.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

Two Sigma Investments first reported a position in RNAC in Q3 2017 and has held it in 28 quarters since. The position peaked at $7.54M in Q1 2021. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Two Sigma Investments held 296,293 shares of Cartesian Therapeutics worth $3.09M as of Q2 2026.
  • Two Sigma Investments bought 128,980 Cartesian Therapeutics shares in Q2 2026, an estimated $955K.
  • Cartesian Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q2 2026, its #2598 holding.
  • Two Sigma Investments first reported a position in Cartesian Therapeutics in Q3 2017 and has held it in 28 quarters since.
  • Two Sigma Investments's Cartesian Therapeutics position peaked at $7.54M in Q1 2021.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.